Abstract

BackgroundCancer-associated fibroblasts are found in the stroma of epithelial tumors. They are characterized by overexpression of the fibroblast activation protein (FAP), a serine protease which was already proven as attractive target for chelator-based theranostics. Unfortunately, the value of gallium-68 labeled tracers is limited by their batch size and the short nuclide half-life. To overcome this drawback, radiolabeling with aluminum fluoride complexes and 6-fluoronicotinamide derivatives of the longer-lived nuclide fluorine-18 was established. The novel compounds were tested for their FAP-specific binding affinity. Uptake and binding competition were studied in vitro using FAP expressing HT-1080 cells. HEK cells transfected with the closely related dipeptidyl peptidase-4 (HEK-CD26) were used as negative control. Small animal positron emission tomography imaging and biodistribution experiments were performed in HT-1080-FAP xenografted nude mice. [18F]AlF-FAPI-74 was selected for PET/CT imaging in a non-small cell lung cancer (NSCLC) patient.ResultsIn vitro, 18F-labeled FAPI-derivatives demonstrated high affinity (EC50 = < 1 nm to 4.2 nm) and binding of up to 80% to the FAP-expressing HT1080 cells while no binding to HEK-CD26 cells was observed. While small animal PET imaging revealed unfavorable biliary excretion of most of the 18F-labeled compounds, the NOTA bearing compounds [18F]AlF-FAPI-74 and -75 achieved good tumor-to-background ratios, as a result of their preferred renal excretion. These two compounds showed the highest tumor accumulation in PET imaging. The organ distribution values of [18F]AlF-FAPI-74 were in accordance with the small animal PET imaging results. Due to its less complex synthesis, fast clearance and low background values, [18F]AlF-FAPI-74 was chosen for clinical imaging. PET/CT of a patient with metastasized non-small cell lung cancer (NSCLC), enabled visualization of the primary tumor and its metastases at the hepatic portal and in several bones. This was accompanied by a rapid clearance from the blood pool and low background in healthy organs.Conclusion[18F]AlF-labeled FAPI derivatives represent powerful tracers for PET. Owing to an excellent performance in PET imaging, FAPI-74 can be regarded as a promising precursor for [18F]AlF-based FAP-imaging.

Highlights

  • Cancer-associated fibroblasts are found in the stroma of epithelial tumors

  • A key characteristic of most Cancer associated fibroblast (CAF) is the expression of the fibroblast activation protein (FAP), a membrane bound serine protease belonging to the dipeptidyl peptidase 4 (DPP4) family

  • The 1-step coupling of the activated esters for all tracers except FAP targeting small molecule radiotracers (FAPI)-75 proceeded with 70–94% yield

Read more

Summary

Introduction

Cancer-associated fibroblasts are found in the stroma of epithelial tumors They are characterized by overexpression of the fibroblast activation protein (FAP), a serine protease which was already proven as attractive target for chelatorbased theranostics. Due to its overexpression in the tumor environment, combined with low expression in most normal tissues, FAP is considered as an important target for diagnostic imaging and anti-cancer therapies in nuclear medicine (Gascard and Tlsty 2016; Lamprecht et al 2018; Lindner et al 2019; Marsh et al 2013; Plava et al 2019; Pure and Lo 2016; Calais 2020). An important advantage of the FAPI-tracers is their ability to detect malignancies with low glucose uptake This improves imaging in patients suffering from tumors such as NSCLC, which are not readily detectable by FDG-PET/CT. A first comparison with the commonly used radiotracer 18F‐FDG revealed a superiority of 68 Ga-FAPI-04 in patients with different tumor entities (Giesel et al 2019a, b, 2021; Kratochwil et al 2019; ·Li ·et al 2021; Kuten et al 2021)

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call